Format

Send to

Choose Destination
See comment in PubMed Commons below
Sci Transl Med. 2013 Sep 11;5(202):202ra122. doi: 10.1126/scitranslmed.3006408.

A molecular signature predictive of indolent prostate cancer.

Author information

1
Department of Urology, Columbia University Medical Center, New York, NY 10029, USA.

Erratum in

  • Sci Transl Med. 2013 Sep 18;5(203):203er9.

Abstract

Many newly diagnosed prostate cancers present as low Gleason score tumors that require no treatment intervention. Distinguishing the many indolent tumors from the minority of lethal ones remains a major clinical challenge. We now show that low Gleason score prostate tumors can be distinguished as indolent and aggressive subgroups on the basis of their expression of genes associated with aging and senescence. Using gene set enrichment analysis, we identified a 19-gene signature enriched in indolent prostate tumors. We then further classified this signature with a decision tree learning model to identify three genes--FGFR1, PMP22, and CDKN1A--that together accurately predicted outcome of low Gleason score tumors. Validation of this three-gene panel on independent cohorts confirmed its independent prognostic value as well as its ability to improve prognosis with currently used clinical nomograms. Furthermore, protein expression of this three-gene panel in biopsy samples distinguished Gleason 6 patients who failed surveillance over a 10-year period. We propose that this signature may be incorporated into prognostic assays for monitoring patients on active surveillance to facilitate appropriate courses of treatment.

PMID:
24027026
PMCID:
PMC3943244
DOI:
10.1126/scitranslmed.3006408
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center